相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann et al.
MOLECULAR CANCER THERAPEUTICS (2020)
The Atypical Protein Kinase C Small Molecule Inhibitor zeta-Stat, and Its Effects on Invasion Through Decreases in PKC-zeta Protein Expression
Tracess Smalley et al.
FRONTIERS IN ONCOLOGY (2020)
PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma
Vladimir Sapon-Cousineau et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window
Jack L. Sloane et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells
Julie Boucau et al.
PLoS Pathogens (2020)
4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat
H. E. De la Torre-Tarazona et al.
BIOCHEMICAL PHARMACOLOGY (2020)
PKC and PKN in heart disease
Valeria Marrocco et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Conditioned stimulus presentations alter anxiety level in fear-conditioned mice
Yujie Zhang et al.
MOLECULAR BRAIN (2019)
An ANGPTL4-ceramide-protein kinase C axis mediates chronic glucocorticoid exposure-induced hepatic steatosis and hypertriglyceridemia in mice
Tzu-Chieh Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diabetic neuropathy
Eva L. Feldman et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Elevated Level of PKMζ Underlies the Excessive Anxiety in an Autism Model
Xiaoli Gao et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Intra-amygdala infusion of zeta inhibitory peptide attenuates neuropathic pain but not inflammatory pain in adult rats
Juan Yao et al.
ANNALS OF PALLIATIVE MEDICINE (2019)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Martin R. Farlow et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
In vitro and in vivo activity of chelerythrine against Candida albicans and underlying mechanisms
Ying Gong et al.
FUTURE MICROBIOLOGY (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Protein Kinase C: Targets to Regenerate Brain Injuries?
Noelia Geribaldi-Doldan et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases
Daniel A. Rodrigues et al.
PHARMACEUTICALS (2019)
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
D. J. DeAngelo et al.
LEUKEMIA (2018)
Protein Kinase C-ζ stimulates colorectal cancer cell carcinogenesis via PKC-ζ/Rac1/Pak1/β-Catenin signaling cascade
S. M. Anisul Islam et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2018)
Protein kinase C: perfectly balanced
Alexandra C. Newton
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2018)
Loss in PKC Epsilon Causes Downregulation of MnSOD and BDNF Expression in Neurons of Alzheimer's Disease Hippocampus
Abhik Sen et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes
Ying Du et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression
Thomas D. Zaikos et al.
JOURNAL OF VIROLOGY (2018)
Atypical PKC, PKC lambda/t, activates beta-secretase and increases A beta(1-40/42) and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer's disease
Mini P. Sajan et al.
NEUROBIOLOGY OF AGING (2018)
Pharmacological Inhibition of Protein Kinase C Reduces West Nile Virus Replication
Ana B. Blazquez et al.
VIRUSES-BASEL (2018)
Oncogenic PKC- activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC- and PKC- specific inhibitors
Wishrawana S. Ratnayake et al.
CELL ADHESION & MIGRATION (2018)
Inhibition of atypical protein kinase C- effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade
Andre H. Apostolatos et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Developmental transitions in amygdala PKC isoforms and AMPA receptor expression associated with threat memory in infant rats
Maya Opendak et al.
SCIENTIFIC REPORTS (2018)
Chelerythrine Attenuates the Inflammation of Lipopolysaccharide-Induced Acute Lung Inflammation Through NF-κB Signaling Pathway Mediated by Nrf2
Lu Fan et al.
FRONTIERS IN PHARMACOLOGY (2018)
PKC inhibition of sotrastaurin has antitumor activity in diffuse large B-cell lymphoma via regulating the expression of MCT-1
Gaomei Chang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2018)
Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
Gabriel Tremblay et al.
COST EFFECTIVENESS AND RESOURCE ALLOCATION (2018)
Antibacterial mechanism of chelerythrine isolated from root of Toddalia asiatica (Linn) Lam
Nan He et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2018)
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Peter Valent et al.
BLOOD (2017)
Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation
Tiffany C. L. Wong et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Protein kinase C and cardiac dysfunction: a review
Raphael M. Singh et al.
HEART FAILURE REVIEWS (2017)
Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis
Wishrawana S. Ratnayake et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Bryostatin Effects on Cognitive Function and PKCε in Alzheimer's Disease Phase IIa and Expanded Access Trials
Thomas J. Nelson et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Protein kinase C in cancer: The top five unanswered questions
Mariana Cooke et al.
MOLECULAR CARCINOGENESIS (2017)
Par3 and aPKC regulate BACE1 endosome-to-TGN trafficking through PACS1
Miao Sun et al.
NEUROBIOLOGY OF AGING (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Divergent response of homologous ATP sites to stereospecific ligand fluorination for selectivity enhancement
Alpesh Ramanlal Patel et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Additive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells
Miao He et al.
PLOS ONE (2017)
Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells
Wanjun Lin et al.
SCIENTIFIC REPORTS (2017)
A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
Yazmin Odia et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
Hongyu Li et al.
ONCOTARGET (2016)
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
Protein Kinase C Activation as a Potential Therapeutic Strategy in Alzheimer's Disease: Is there a Role for Embryonic Lethal Abnormal Vision-like Proteins?
Virpi Talman et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inhibition of JAK3 and PKC via Immunosuppressive Drugs Tofacitinib and Sotrastaurin Inhibits Proliferation of Human B Lymphocytes In Vitro
M. N. Martina et al.
TRANSPLANTATION PROCEEDINGS (2016)
Compensation for PKMζ in long-term potentiation and spatial long-term memory in mutant mice
Panayiotis Tsokas et al.
ELIFE (2016)
Zeta Inhibitory Peptide as a Novel Therapy to Control Chronic Visceral Hypersensitivity in a Rat Model
Ying Tang et al.
PLoS One (2016)
Protein Kinase C Inhibitor Sotrastaurin in De Novo Liver Transplant Recipients: A Randomized Phase II Trial
A. Pascher et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Zeta Inhibitory Peptide Disrupts Electrostatic Interactions That Maintain Atypical Protein Kinase C in Its Active Conformation on the Scaffold p62
Li-Chun Lisa Tsai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Zeta Inhibitory Peptide, a Candidate Inhibitor of Protein Kinase Mζ, Is Excitotoxic to Cultured Hippocampal Neurons
Noa Sadeh et al.
JOURNAL OF NEUROSCIENCE (2015)
A Mixed-Methods Feasibility Trial of Protein Kinase C Iota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients
Aminah Jatoi et al.
ONCOLOGY (2015)
A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion
Amanda M. Butler et al.
ONCOTARGET (2015)
PKCε Deficits in Alzheimer's Disease Brains and Skin Fibroblasts
Tapan K. Khan et al.
JOURNAL OF ALZHEIMERS DISEASE (2015)
Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation
Mini P. Sajan et al.
JOURNAL OF LIPID RESEARCH (2015)
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study
Lindsay B. Kilburn et al.
NEURO-ONCOLOGY (2015)
Protein Kinase C (PKC)ζ Pseudosubstrate Inhibitor Peptide Promiscuously Binds PKC Family Isoforms and Disrupts Conventional PKC Targeting and Translocation
Amy S. Bogard et al.
MOLECULAR PHARMACOLOGY (2015)
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial
A. Michael Lincoff et al.
EUROPEAN HEART JOURNAL (2014)
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma
Eric Jourdan et al.
LEUKEMIA & LYMPHOMA (2014)
Protein kinase C and cancer: what we know and what we do not
R. Garg et al.
ONCOGENE (2014)
Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients
H. Tedesco-Silva et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results
G. R. Russ et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Phase I dose escalation study of the PKCi inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer
Aaron S. Mansfield et al.
ANTI-CANCER DRUGS (2013)
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
Cynthia X. Ma et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Staurosporine Analogues from Microbial and Synthetic Sources and Their Biological Activities
B. Park et al.
CURRENT MEDICINAL CHEMISTRY (2013)
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Robert Dreicer et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
Ivana Gojo et al.
INVESTIGATIONAL NEW DRUGS (2013)
Randomized, Phase II, Placebo-Controlled, Double- Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer
Ignace B. Vergote et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prkcz null mice show normal learning and memory
Anna M. Lee et al.
NATURE (2013)
PKM-ζ is not required for hippocampal synaptic plasticity, learning and memory
Lenora J. Volk et al.
NATURE (2013)
Matching biochemical and functional efficacies confirm ZIP as a potent competitive inhibitor of PKMζ in neurons
Yudong Yao et al.
NEUROPHARMACOLOGY (2013)
The Safety and Efficacy of KAI-1678 An Inhibitor of Epsilon Protein Kinase C (εPKC)Versus Lidocaine and Placebo for the Treatment of Postherpetic Neuralgia: A Crossover Study Design
Michael J. Cousins et al.
PAIN MEDICINE (2013)
The Effect of the Oral PKC β Inhibitor Ruboxistaurin on Vision Loss in Two Phase 3 Studies
Matthew J. Sheetz et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2013)
Protein kinase C (PKC) isozyme-specific substrates and their design
Jeong-Hun Kang et al.
BIOTECHNOLOGY ADVANCES (2012)
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer
Robert A. Wolff et al.
CANCER (2012)
In vivo effects of ICA-1 on breast cancer and glioma xenografts
Mildred E. Acevedo-Duncan
CANCER RESEARCH (2012)
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study
Robert J. Morgan et al.
INVESTIGATIONAL NEW DRUGS (2012)
Cellular Pharmacology of Protein Kinase Mζ (PKMζ) Contrasts with Its in Vitro Profile IMPLICATIONS FOR PKMζ AS A MEDIATOR OF MEMORY
Alyssa X. Wu-Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
Christelle Clement-Duchene et al.
LUNG CANCER (2012)
A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer
Bjorn H. Gronberg et al.
LUNG CANCER (2012)
Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-i
Mini P. Sajan et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Sotrastaurin, a Novel Small Molecule Inhibiting Protein-Kinase C: Randomized Phase II Study in Renal Transplant Recipients
S. Friman et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
Paula M. Fracasso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas
Tara L. Naylor et al.
CANCER RESEARCH (2011)
A Phase I Clinical Trial of Safingol in Combination with Cisplatin in Advanced Solid Tumors
Mark A. Dickson et al.
CLINICAL CANCER RESEARCH (2011)
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies
Lydia Usha et al.
GYNECOLOGIC ONCOLOGY (2011)
A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma
Prajit Pillai et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study
Donald A. Richards et al.
INVESTIGATIONAL NEW DRUGS (2011)
PKC ε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice
Jarin Hongpaisan et al.
JOURNAL OF NEUROSCIENCE (2011)
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia
Gerald E. Marti et al.
LEUKEMIA & LYMPHOMA (2011)
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
Christiane Querfeld et al.
LEUKEMIA & LYMPHOMA (2011)
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
Nicholas Butowski et al.
NEURO-ONCOLOGY (2011)
Sustained inhibition of PKC alpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model
J. Kim et al.
ONCOGENE (2011)
ATP Competitive Protein Kinase C Inhibitors Demonstrate Distinct State-Dependent Inhibition
Ida M. Smith et al.
PLOS ONE (2011)
EFFECT OF RUBOXISTAURIN (RBX) ON VISUAL ACUITY DECLINE OVER A 6-YEAR PERIOD WITH CESSATION AND REINSTITUTION OF THERAPY Results of an Open-Label Extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)
Matthew J. Sheetz et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic Carcinoma
Anthony P. Lam et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Shivaani Kummar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Protein Kinase C-β Gene Variants, Pathway Activation, and Enzastaurin Activity in Lung Cancer
Sang-Haak Lee et al.
CLINICAL LUNG CANCER (2010)
Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Moises Perez et al.
CURRENT HIV RESEARCH (2010)
HIV-1 Tat-peptide inhibits protein kinase C and protein kinase A through substrate competition
Elina Ekokoski et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Ruboxistaurin, a PKC beta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt
Shinsuke Nakamura et al.
EXPERIMENTAL EYE RESEARCH (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Alberto Chiappori et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner
Rajeev Mehla et al.
PLOS ONE (2010)
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant
Paul M. Barr et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
The Chemical Biology of Protein Phosphorylation
Mary Katherine Tarrant et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Protein Kinase Cβ Is an Effective Target for Chemoprevention of Colon Cancer
Alan P. Fields et al.
CANCER RESEARCH (2009)
Protein kinase C in heart failure: a therapeutic target?
Suresh Selvaraj Palaniyandi et al.
CARDIOVASCULAR RESEARCH (2009)
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
Lida Mina et al.
INVESTIGATIONAL NEW DRUGS (2009)
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine
Hirofumi Nakano et al.
JOURNAL OF ANTIBIOTICS (2009)
Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a Potent and Selective Inhibitor of Protein Kinase C Isotypes
Juergen Wagner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation
Jean-Pierre Evenou et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
PKC-β1 Mediates Glucose-Induced Akt Activation and TGF-β1 Upregulation in Mesangial Cells
Dongcheng Wu et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2008)
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
Geoffrey Y. Ku et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Atypical protein kinase CL expression and aurothiomalate sensitivity in human lung cancer cells
Roderick P. Regala et al.
CANCER RESEARCH (2008)
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction
Matthew T. Roe et al.
CIRCULATION (2008)
Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro
Nerijus Lamanauskas et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis
Hans Skvara et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
Antonino Neri et al.
LEUKEMIA & LYMPHOMA (2008)
Structural basis of protein kinase C isoform function
Susan F. Steinberg
PHYSIOLOGICAL REVIEWS (2008)
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
Antonio Jimeno et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
Karoline Gleixner et al.
HAEMATOLOGICA (2007)
Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials
Solomon Tesfaye et al.
DIABETES CARE (2007)
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium
Stephen Welch et al.
GYNECOLOGIC ONCOLOGY (2007)
Diabetic neuropathy - a review
Gerard Said
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors
Martin J. Edelman et al.
CLINICAL CANCER RESEARCH (2007)
Role of the Akt/FoxO3a pathway in TGF-β1-mediated mesangial cell dysfunction:: A novel mechanism related to diabetic kidney disease
Mitsuo Kato et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Aurothiomalate inhibits transformed growth by targeting the PB1 domain of protein kinase Cι
Eda Erdogan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines
Mujahid A. Rizvi et al.
MOLECULAR CANCER THERAPEUTICS (2006)
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
JA Ajani et al.
INVESTIGATIONAL NEW DRUGS (2006)
A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies
D Schaar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
P Ritch et al.
LUNG CANCER (2006)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-sinall-cell lung cancer
L Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma
AC Peterson et al.
INVESTIGATIONAL NEW DRUGS (2006)
A novel small-molecule inhibitor of protein kinase Cι blocks transformed growth of non-small-cell lung cancer cells
M Stallings-Mann et al.
CANCER RESEARCH (2006)
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study
SJ Hotte et al.
ANNALS OF ONCOLOGY (2006)
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT:: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
KV Gleixner et al.
BLOOD (2006)
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
Cesar Sanchez et al.
NATURAL PRODUCT REPORTS (2006)
Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo
MH Yoo et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation
J Gotlib et al.
BLOOD (2005)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California cancer consortium phase I pharmacokinetic and molecular correlative trial
PN Lara et al.
CLINICAL CANCER RESEARCH (2005)
Features of selective kinase inhibitors
ZA Knight et al.
CHEMISTRY & BIOLOGY (2005)
Protein kinase Cβ inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy
DJ Kelly et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors
J Kortmansky et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas
SA Grossman et al.
NEURO-ONCOLOGY (2005)
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study
F Nezhat et al.
GYNECOLOGIC ONCOLOGY (2004)
Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1
D Komander et al.
STRUCTURE (2004)
A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21-day infusion to patients with advanced ovarian carcinoma
R Advani et al.
CANCER (2004)
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
S Rao et al.
ANNALS OF ONCOLOGY (2004)
Solution structure of atypical protein kinase CPB1 domain and its mode of interaction with ZIP/p62 and MEK5
Y Hirano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
DK Armstrong et al.
INVESTIGATIONAL NEW DRUGS (2003)
A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
S Madhusudan et al.
BRITISH JOURNAL OF CANCER (2003)
A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma
AR Clamp et al.
BRITISH JOURNAL OF CANCER (2003)
Translocation of glomerular p47phox and p67phox by protein kinase C-β activation is required for oxidative stress in diabetic nephropathy
M Kitada et al.
DIABETES (2003)
Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins
T Lamark et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Protein kinase Cβ selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons
H Kim et al.
DIABETES (2003)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes
T Yokota et al.
DIABETES (2003)
Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes - Role of oxidants and protein kinase-C activation
T Abiko et al.
DIABETES (2003)
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer
JD Winegarden et al.
LUNG CANCER (2003)
Inhibition of protein kinase C by resveratrol
SJ Slater et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2003)
A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma - A National Cancer Institute of Canada Clinical Trials Group study
RG Tozer et al.
INVESTIGATIONAL NEW DRUGS (2002)
Inhibition by melittin of phosphorylation by protein kinase C of annexin I from cow mammary gland
N Katoh
JOURNAL OF VETERINARY MEDICAL SCIENCE (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
Protein kinase Mζ is necessary and sufficient for LTP maintenance
DSF Ling et al.
NATURE NEUROSCIENCE (2002)
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
DG Pfister et al.
INVESTIGATIONAL NEW DRUGS (2002)
Opposing cardioprotective actions and parallel hypertrophic effects of δPKC and εPKC
L Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Binding specificity for RACK1 resides in the V5 region of βII protein kinase C
EG Stebbins et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions
AC Newton
CHEMICAL REVIEWS (2001)
Protein kinase C ε suppresses Aβ production and promotes activation of α-secretase
GF Zhu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Phase II evaluation of bryostatin-1 in metastatic melanoma
AY Bedikian et al.
MELANOMA RESEARCH (2001)
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
FH Blackhall et al.
BRITISH JOURNAL OF CANCER (2001)
Phase II study of bryostatin 1 in patients with relapsed multiple myeloma
ML Varterasian et al.
INVESTIGATIONAL NEW DRUGS (2001)
Interaction of benzo[c]phenanthridine and protoberberine alkaloids with animal and yeast cells
I Slaninova et al.
CELL BIOLOGY AND TOXICOLOGY (2001)
Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer
B Brockstein et al.
INVESTIGATIONAL NEW DRUGS (2001)
A novel neuroprotective mechanism of riluzole: Direct inhibition of protein kinase C
KM Noh et al.
NEUROBIOLOGY OF DISEASE (2000)
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
PR Graves et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
